<DOC>
	<DOCNO>NCT02560272</DOCNO>
	<brief_summary>The study evaluate safety immunogenicity haemophilus influenzae type b conjugate vaccine ( Hib ) Healthy Children 2 Months 5 Years Age previously immunize Hib vaccine . Children 2 5 month age receive 3 dos Hib vaccine , Children 6 11 month age receive 2 dos Hib vaccine , Children 1 5 year age receive 1 dose Hib vaccine , dose give approximately 1 month apart .</brief_summary>
	<brief_title>Safety Immunogenicity Haemophilus Influenzae Type b Conjugate Vaccine，Freeze-dried</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Haemophilus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy permanent residence 2 month 5 year old . Subjects investigator believe comply requirement protocol enrol study . Subjects parent/guardian able attend schedule visit comply study procedure . Axillary temperature ≤37.0 ℃ . History Haemophilus influenzae type b infection vaccination Haemophilus influenzae type b conjugate vaccine . Allergic history SAE vaccination , allergy , urticaria , dyspnea , angioedema , celialgia . Receipt blood bloodderived product 3 month precede vaccination Participation another clinical study investigate vaccine , drug 30 day precede vaccination . Receipt live virus vaccine 15 day precede vaccination . Receipt subunit vaccine inactivate vaccine 7 day vaccination . Febrile illness ( temperature ≥ 38°C ) 3 day acute illness/infection 7 day precede vaccination . Thrombocytopenia . History treatment thyroid gland disease . Functional anatomic asplenia . History eclampsia , epilepsy , encephalopathy mental disease family disease . Any condition , judgment investigator , may affect trial assessment .</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>vaccine</keyword>
	<keyword>haemophilus influenzae type b</keyword>
</DOC>